Skip to main content
logo
Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
27.18
-0.39 (-1.41%)
Jul 31, 2026, 4:00 PM EDT - Market closed

Tango Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
56.9962.3842.0736.5324.8637.04
Revenue Growth
97.27%48.29%15.17%46.93%-32.89%383.83%
Gross Profit
56.9962.3842.0736.5324.8637.04
Operating Income
-117.53-111.29-145.6-114.17-111.07-58.19
Net Income
-107.23-101.59-130.3-101.74-108.18-58.24
Earnings Per Share
-0.83-0.87-1.19-1.08-1.23-0.94
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
379.84343.14257.92336.89366.13485.26
Total Debt
32.7933.5736.4938.9241.131.5
Net Cash (Debt)
347.05309.57221.42297.97325483.75
Net Cash Growth
93.04%39.81%-25.69%-8.32%-32.82%165.16%
Net Cash Per Share
2.762.662.033.153.707.79

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-141.55-138.89-131.5-117.98-109.08-59.53
Capital Expenditures
-1-1.05-0.75-1.53-7.69-1.84
Free Cash Flow
-142.54-139.93-132.26-119.51-116.77-61.36
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-206.22%-178.39%-346.09%-312.57%-446.79%-157.09%
Pretax Margin
-188.20%-162.85%-309.24%-278.18%-434.92%-156.43%
Profit Margin
-188.25%-162.84%-308.75%-277.81%-434.71%-155.64%
FCF Margin
-250.11%-224.31%-314.38%-327.18%-469.72%-165.66%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
68.9819.317.9127.7025.7225.87